MedTrace Logo

Imaging and Biomarkers of Hypoxia in Solid Tumors

NCT01123005 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2017-11-06

No results posted yet for this study

Summary

Hypoxia, meaning a lack of oxygen, has been associated strongly with a wide range of human cancers. Hypoxia occurs when tumor growth exceeds the ability of blood vessels to supply the tumor with oxygenated blood. It is currently understood that hypoxic tumors are more aggressive. Current methods for measuring hypoxia include invasive procedures such as tissue biopsy, or insertion of an electrode into the tumor. EF5-PET may be a non-invasive way to measure tumor hypoxia.

Conditions

  • Neoplasms

Interventions

PROCEDURE

PET Scan

radiation calculated per patient

DRUG

EF5

10 mCi, IV

DRUG

Carbogen

Calculated per patient

DRUG

Dichloroacetate

Sponsors & Collaborators

Principal Investigators

  • Dr. Billy W. Loo Jr. M.D. Ph.D. · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2015-08-21
Completion
2015-08-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01123005 on ClinicalTrials.gov